Ohnari S, Meguro H, Nonaka C, Tajima T, Takahashi S, Fujii R
Jpn J Antibiot. 1985 Mar;38(3):671-8.
Cefminox (CMNX, MT-141) was evaluated for its safety and efficacy in children. Fifteen cases of bacterial infections were treated with intravenous bolus injections of 30 to 100 mg/kg/day of CMNX. Each 5 cases of acute respiratory tract, urinary tract, and gastrointestinal infections were included. All the cases were cured after the CMNX therapy. No adverse reactions were encountered with the therapy. The serum half-life was approximately 1.5 to 2 hours after intravenous bolus injection in children. The data suggest that CMNX is a safe and effective antibiotic when used in children with susceptible bacterial infections.
对头孢米诺（CMNX，MT - 141）在儿童中的安全性和有效性进行了评估。15例细菌感染患儿接受了静脉推注，剂量为每天30至100mg/kg的CMNX治疗。其中急性呼吸道、泌尿系统和胃肠道感染各5例。所有病例在接受CMNX治疗后均治愈。治疗过程中未出现不良反应。儿童静脉推注后血清半衰期约为1.5至2小时。数据表明，CMNX用于患有易感细菌感染的儿童时是一种安全有效的抗生素。
